• TDP-43 Oligomerization, RNA Binding, and Aggregation

  2026-08-18

  The reference study separates two TDP-43 failure modes—loss of oligomerization and loss of RNA binding—and shows that they produce different aggregate locations and formation pathways. Its combination of structure-based variants, human neurons, near-physiological expression systems, and proteasome-impairment experiments provides a mechanistic framework for interpreting heterogeneous TDP-43 pathology in ALS and FTLD.

• CA-074 Me for Cathepsin B and Lysosomal Assays

  2026-08-18

  CA-074 Me is a membrane-permeable cathepsin B inhibitor for separating lysosomal protease activity from upstream cell-death signaling. This practical guide connects LMP imaging, necroptosis workflows, apoptosis assay design, and TNF-α-induced liver injury research with product-specific handling and troubleshooting.

• JNJ-10198409: PDGF Receptor Inhibitor Workflows

  2026-08-17

  JNJ-10198409 is a nanomolar ATP-competitive tool for dissecting PDGF-BB receptor signaling in proliferation, angiogenesis, cancer, and fibrotic disorder models. This practical guide connects dose-response design with time-resolved phosphorylation, phenotype, and troubleshooting workflows.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-17

  Song et al. show that murine norovirus uses the host membrane-rupture protein NINJ1 to release the viral NS1 protein during caspase-3-dependent cell death. The work connects apoptosis, unconventional protein secretion, and enteric viral pathogenesis, while providing a framework for testing how NINJ1 controls cargo release.

• Staurosporine: From Kinase Probe to Cancer Strategy

  2026-08-16

  Staurosporine is more than a classic apoptosis trigger: its broad kinase activity can help translational researchers test how signaling networks connect tumor-cell survival, ERM-driven invasion, and VEGF-associated angiogenesis—provided its interpretive limits are built into the experimental design.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-08-15

  This study identifies circulating soluble GPNMB as a functional marker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF–epithelial niche features, and clinicopathological data, the authors develop a multimodal framework that links tumor–immune biology with treatment-response prediction.

• Etoposide (VP-16) for DNA Damage Assays

  2026-08-14

  Etoposide (VP-16) provides a practical way to create controlled topoisomerase II–dependent DNA damage for cytotoxicity, apoptosis, and repair-pathway studies. This guide connects dose selection and assay troubleshooting with a senescence-focused reference model, helping researchers distinguish DNA damage, cell death, and senomorphic responses.

• Chloroquine in Cancer Therapy: Pharmacology and Evidence

  2026-08-14

  The 2024 review by Liu and colleagues synthesizes how Chloroquine suppresses tumor progression through both autophagy-dependent and autophagy-independent mechanisms. Its main practical contribution is to connect lysosomal pharmacology with apoptosis, necroptosis, signaling modulation, combination therapy, and the safety constraints that shape clinical translation.

• Vancomycin and the Immune–Microbiome Translation Gap

  2026-08-13

  Vancomycin offers a precise bacterial cell wall perturbation for resistance and microbiome research, but translating antibiotic-associated immune findings requires disciplined controls. This article connects peptidoglycan precursor binding with the Th1/Th2 and gut-flora findings reported in an allergic rhinitis rat study while defining a practical path toward more interpretable translational experiments.

• Step Biosensor Tracks Native Protein Dynamics

  2026-08-13

  The reference study introduces circStep, an allosteric genetically encoded biosensor that converts endogenous protein binding into fluorescence from a dual-locked fluorogenic RNA aptamer module. This design enables live-cell visualization of native protein abundance, localization, and relocalization without directly tagging or overexpressing the protein of interest.

• Prednisolone Workflows for Glucocorticoid Research

  2026-08-12

  Prednisolone provides a high-purity synthetic glucocorticoid control for dissecting receptor signaling, inflammatory phenotypes, and cellular responses alongside emerging ERAD-based degradation assays. This workflow-focused guide shows how to use it as a pathway comparator without mistakenly treating it as the desonide-derived ERAD warhead described in the reference study.

• Gepotidacin (GSK2140944) Research Workflows

  2026-08-12

  Gepotidacin enables mechanism-led antibacterial research from bacterial growth inhibition to DNA gyrase cleavage assays. This workflow connects dose-response screening, resistance analysis, and translational interpretation while emphasizing compound handling and assay troubleshooting.

• AZD0156: A Translational Strategy for ATM Inhibition

  2026-08-11

  AZD0156 offers a highly selective way to interrogate ATM kinase biology, connect DNA double-strand break repair with metabolic adaptation, and design more informative combination studies in cancer therapy research.

• STT3B, ICG, and α-Amanitin Cytotoxicity

  2026-08-11

  The reference study combines a genome-wide CRISPR knockout screen, computational drug screening, and validation in cells, liver organoids, and mice to identify STT3B as a critical determinant of α-amanitin toxicity. Its findings position indocyanine green as a candidate STT3B inhibitor and provide a mechanistic framework for studying mushroom toxin cytotoxicity beyond direct RNA polymerase II inhibition.

• JTW and Coptisine Rewire PCOS Steroidogenesis

  2026-08-10

  The 2025 Phytomedicine study identifies SIRT1 ubiquitination and mitochondrial cholesterol import as a mechanistic link between Jiao-tai-wan, coptisine, and abnormal ovarian steroidogenesis in a DHEA-induced PCOS rat model. Its integrated animal, cellular, transcriptomic, imaging, and target-validation strategy provides a useful framework for studying how mitochondrial steroidogenic control contributes to PCOS phenotypes.

17129 records 1/1142 page Next 12345 下5页 Last page